PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy
2 other identifiers
interventional
31
2 countries
32
Brief Summary
This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Sep 2002
Longer than P75 for phase_2
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 8, 2002
CompletedFirst Posted
Study publicly available on registry
August 12, 2002
CompletedStudy Start
First participant enrolled
September 1, 2002
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2007
CompletedMarch 12, 2009
March 1, 2009
4.8 years
August 8, 2002
March 11, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Adverse Events and DLTs will be evaluated by the Investigator and summarized.
indeterminate
Secondary Outcomes (1)
No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings.
indeterminate
Study Arms (1)
1
EXPERIMENTALPatients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
Interventions
PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
Eligibility Criteria
You may qualify if:
- Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.
You may not qualify if:
- The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (32)
Pfizer Investigational Site
Berkely, California, 94704, United States
Pfizer Investigational Site
Gilroy, California, 95020, United States
Pfizer Investigational Site
Hollister, California, 95023, United States
Pfizer Investigational Site
Los Angeles, California, 90057, United States
Pfizer Investigational Site
Los Angeles, California, 91342, United States
Pfizer Investigational Site
Palm Springs, California, 92262, United States
Pfizer Investigational Site
Stanford, California, 94305, United States
Pfizer Investigational Site
New Haven, Connecticut, 06504, United States
Pfizer Investigational Site
Bonita Springs, Florida, 34135, United States
Pfizer Investigational Site
Bradenton, Florida, 34209, United States
Pfizer Investigational Site
Cape Coral, Florida, 33990, United States
Pfizer Investigational Site
Fort Myers, Florida, 33901, United States
Pfizer Investigational Site
Fort Myers, Florida, United States
Pfizer Investigational Site
Naples, Florida, 34102, United States
Pfizer Investigational Site
Plantation, Florida, 33324, United States
Pfizer Investigational Site
Port Charlotte, Florida, 33980, United States
Pfizer Investigational Site
Sarasota, Florida, 34232, United States
Pfizer Investigational Site
Venice, Florida, 34285, United States
Pfizer Investigational Site
Venice, Florida, 34292, United States
Pfizer Investigational Site
Chicago, Illinois, 60611-3124, United States
Pfizer Investigational Site
Chicago, Illinois, 60611, United States
Pfizer Investigational Site
Vincennes, Indiana, 47591, United States
Pfizer Investigational Site
Ann Arbor, Michigan, 48109, United States
Pfizer Investigational Site
Olive Branch, Mississippi, 38654, United States
Pfizer Investigational Site
Oxford, Mississippi, 38655, United States
Pfizer Investigational Site
Livingston, New Jersey, 07039, United States
Pfizer Investigational Site
Asheville, North Carolina, 28801, United States
Pfizer Investigational Site
Portland, Oregon, 97213, United States
Pfizer Investigational Site
Collierville, Tennessee, 38107, United States
Pfizer Investigational Site
Memphis, Tennessee, 38017, United States
Pfizer Investigational Site
Memphis, Tennessee, 38104, United States
Pfizer Investigational Site
Cologne, 50931, Germany
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 8, 2002
First Posted
August 12, 2002
Study Start
September 1, 2002
Primary Completion
June 1, 2007
Study Completion
June 1, 2007
Last Updated
March 12, 2009
Record last verified: 2009-03